Promising HAE prevention drug now available for kids in Follow-Up study
NCT ID NCT07159464
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study offers children aged 2 to 11 with hereditary angioedema (HAE) continued access to garadacimab, a lab-made antibody that helps prevent sudden, painful swelling attacks. Participants must have completed a prior study and shown good response with few or no attacks. The goal is to keep providing this preventive treatment while monitoring long-term safety and benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Garadacimab (a lab-made antibody injected under the skin)
- What this could lead to
- If successful, this could offer a safe, ongoing prevention option for children with hereditary angioedema, reducing the frequency of painful swelling attacks.
- What could go wrong
- This is an open-label extension study with no placebo group, so results may be less reliable. Long-term safety in young children is still being monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- HAE patients and caregivers speak out: the hidden costs of On-Demand treatment
- Real-world study shows lanadelumab keeps HAE attacks at bay for many patients
- Takhzyro under the microscope: Real-World safety check for rare swelling disease
- New hope for HAE patients: experimental drug aims to slash attack rate
- New RNA drug shows promise in preventing HAE attacks in ongoing study
- New drug TAKHZYRO tracked for Long-Term safety in rare swelling disorder